Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242731 | 0.85 | KDM4E (0.45) | KMT2ATDP1MAPTKDM4EBLM | |
| SCHEMBL29998210 | 0.85 | KDM4E (0.45) | KMT2ATDP1MAPTKDM4EBLM | |
| SCHEMBL8808836 | 0.81 | LMNA (0.46) | LMNAKMT2ATDP1MAPTKDM4E | |
| SCHEMBL5845662 | 0.80 | CYP19A1 (0.44) | — | |
| SCHEMBL31128153 | 0.80 | LMNA (0.45) | LMNAKMT2ATDP1MAPTKDM4E | |
| SCHEMBL31128150 | 0.80 | LMNA (0.45) | LMNAKMT2ATDP1MAPTKDM4E | |
| SCHEMBL563664 | 0.79 | ALDH1A1 (0.50) | LMNAKMT2ATDP1MAPTS1PR4 | |
| SCHEMBL29779688 | 0.79 | ALDH1A1 (0.47) | LMNAKMT2ATDP1MAPTHTT | |
| SCHEMBL1625178 | 0.79 | ALDH1A1 (0.47) | LMNAKMT2ATDP1MAPTHTT | |
| SCHEMBL29672031 | 0.79 | ALDH1A1 (0.50) | LMNAKMT2ATDP1MAPTS1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748839-A1 | POLYCYCLIC COMPOUND AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| US-12539294-B2 | Combination of an azetidine LPA1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-02-03 | — | — | US | disclosed |
| WO-2025021048-A1 | POLYCYCLIC COMPOUND AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2025-01-30 | — | — | WO | disclosed |
| CN-119330949-A | Polycyclic compound and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-117024404-A | Benzopyridine derivatives and uses thereof | 四川汇宇制药股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230000846-A1 | COMBINATION OF AN AZETIDINE LPA1 RECEPTOR ANTAGONIST WITH PIRFENIDONE AND/OR NINTEDANIB FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-01-05 | — | — | US | disclosed |
| EP-4069227-A1 | COMBINATION OF AN AZETIDINE LPA1 RECEPTOR ANTAGONIST WITH PIRFENIDONE AND/OR NINTEDANIB FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | Idorsia Pharmaceuticals Ltd (CH) | 2022-10-12 | — | — | EP | disclosed |
| CN-114761001-A | Combination of azetidine LPA1 receptor antagonists with anti-fibrotic agents | 爱杜西亚药品有限公司 | 2022-07-15 | — | — | CN | disclosed |
| WO-2021110805-A1 | COMBINATION OF AN AZETIDINE LPA1 RECEPTOR ANTAGONIST WITH PIRFENIDONE AND/OR NINTEDANIB FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-06-10 | — | — | WO | disclosed |
| EP-0784612-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539294-B2 | Combination of an azetidine LPA1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases | LPAR2, LPAR1, LPAR3 | LMNA 904/4885KMT2A 1246/4885TDP1 2538/4885 |
| US-20230000846-A1 | COMBINATION OF AN AZETIDINE LPA1 RECEPTOR ANTAGONIST WITH PIRFENIDONE AND/OR NINTEDANIB FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | LPAR1, LPAR2, LPAR3 | LMNA 794/4885KMT2A 2541/4885TDP1 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.